Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer

Robert L. Coleman, MD, FACOG, FACS, chief scientific officer of The US Oncology Network, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.

Findings from the trial, which were presented during the 2020 ESMO Virtual Congress, showed that the novel antibody-drug conjugate tisotumab vedotin elicited a 24% overall response rate, with a 7% complete response rate in patients with previously treated recurrent or metastatic cervical cancer.

According to Coleman, more effective treatments are needed for this patient population.

Moreover, the hope is that tisotumab vedotin will receive regulatory approval so that it can be used in the clinical setting for patients, Coleman says.

Ongoing trials are evaluating the agent versus standard of care treatment, as well as in combination with checkpoint inhibitors, explains Coleman.

Pending additional positive data, tisotumab vedotin has the potential to become an integral agent in the management of patients with recurrent or metastatic cervical cancer, concludes Coleman.